Within the past decade, premenstrual syndrome (PMS) has become the sub
ject of rigorous scientific scrutiny. As a result, diagnostic criteria
have been developed, and the pathophysiology of the disorder has been
partially elucidated. The preponderance of evidence suggests that the
disorder is the result of the interaction of cyclic changes in estrog
en and progesterone with specific neurotransmitters. Serotonin and gam
ma-amino butyric acid (GABA) appear to be especially important in this
regard. Increased understanding of PMS has enabled the development of
specific treatment modalities that, unlike previous prescriptions, ha
ve demonstrated efficacy in rigorous and reproducible studies.